Andersson F
Battelle Medical Technology and Policy Centre, London, UK.
Health Policy. 1992 May;21(1):17-34. doi: 10.1016/0168-8510(92)90126-v.
With an increasing trend in health care consumption--together with the introduction of an increasing number of new medical technologies-- governments, insurance companies and other third party payers seek new ways of limiting increases in consumption, as well as limiting the use of new medical technologies to the most efficient ones (clinically, economically). One particular area of focus in this context is the pharmaceutical sector, where the innovational rate of new technologies (drugs) has been high. One of the forerunners in the areas of health care cost containment and regulatory health economics is Norway. This country has succeeded in keeping drug prices and drug consumption at moderate levels, as well as keeping the number of new drugs to a relatively modest level. This study describes the Norwegian drug regulatory process, the Norwegian drug market, the Norwegian cost-containment policies and future regulatory perspectives. For many European countries and in North America, where stricter price and reimbursement regulations are considered, the Norwegian drug regulatory process presents an interesting example of how a strict regulatory environment may affect the availability of drugs, as well as drug prices, drug reimbursement and drug consumption.
随着医疗保健消费呈上升趋势，再加上越来越多新医疗技术的引入，政府、保险公司和其他第三方支付方正在寻找新方法来限制消费增长，并将新医疗技术的使用限制在最有效的技术（临床和经济方面）。在这种背景下，一个特别受关注的领域是制药行业，该行业新技术（药物）的创新率一直很高。挪威是医疗保健成本控制和监管卫生经济学领域的先驱之一。该国成功地将药品价格和药品消费维持在适度水平，并将新药数量保持在相对适度的水平。本研究描述了挪威的药品监管流程、挪威药品市场、挪威的成本控制政策以及未来的监管前景。对于许多考虑实施更严格价格和报销规定的欧洲国家和北美国家而言，挪威的药品监管流程展示了一个有趣的例子，即严格的监管环境如何影响药品的可及性、药品价格、药品报销和药品消费。
